Valion Bio Stockholders Grant Board 1-for-2 to 1-for-12 Reverse Split Authority
VBIO is trading near its 52-week low of $0.472 (8.2% above the low) on light trading volume (0.1× avg).
Summary
Valion Bio shareholders approved giving the board authority to reverse-split the stock anywhere from 1-for-2 to 1-for-12 within twelve months, and approved 272,000 additional shares for the 2021 equity plan. The vote clears the way for another split just months after the August 1-for-25.
Key Events · Corporate Governance and Compliance · VBIO
-
Board Wins Reverse Split Authority
Stockholders approved discretionary authority for the board to amend the charter for a reverse split of not less than 1-for-2 and not greater than 1-for-12, exercisable any time within twelve months without further stockholder approval.
-
Equity Plan Reserve Raised 272,000 Shares
The 2021 Equity Incentive Plan reserve was increased by 272,000 shares, effective on stockholder approval; no other plan terms changed.
-
Split Vote Draws Meaningful Opposition
The reverse-split proposal passed 681,523 to 444,153, with 9 abstentions — roughly 39% of votes cast were against it.
-
Second Split in Under Three Months
Follows the 1-for-25 reverse split effective August 31, 2026, which was itself aimed at regaining Nasdaq's $1.00 minimum bid price.
Analysis · VBIO · Life Sciences
Valion Bio now has a twelve-month window to execute a reverse split at a ratio of its choosing, without another shareholder vote. That matters because the company is fighting to hold its Nasdaq listing after a 1-for-25 split in August 2026, and it is down to roughly $2.1M in cash with going-concern doubt already on the record. A second split within months would be a mechanical fix to the $1.00 bid price, not a fix to the business — and it comes alongside a 272,000-share increase to the equity plan reserve, which adds to the share overhang. The 52.22% turnout and the 444,153 votes against the split authority show a meaningful slice of holders are not on board.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.47 to $67.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.